Date: 2015-10-13
Type of information: Nomination
Compound:
Company: Sucampo Pharmaceuticals 5USA - M)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 13, 2015, Sucampo Pharmaceuticals announced that Timothy P. Walbert has joined Sucampo's Board of Directors. Mr. Walbert currently serves as Chairman, President and Chief Executive Officer of Horizon Pharma.
Mr. Walbert joined Horizon in June 2008 as President and Chief Executive Officer and has served as Chairman of the Board of Directors since 2010. Prior to joining Horizon, Mr. Walbert served as President, Chief Executive Officer and Director of IDM Pharma, which was acquired by Takeda in June 2009 . Prior to IDM, Mr. Walbert served as Executive Vice President, Commercial Operations at NeoPharm. From 2001 to 2005, Mr. Walbert served as Divisional Vice President and General Manager, Immunology, where he led the global development and launch of the multi-indication biologic Humira and as Divisional Vice President, Global Cardiovascular Strategy at Abbott, now AbbVie . From 1998 to 2001, Mr. Walbert served as Director, Celebrex North America and Arthritis Team Leader, Asia Pacific , Latin America and Canada at G.D. Searle & Company . From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. , Inc. and Wyeth.
Mr. Walbert received his B.A. in business from Muhlenberg College . Mr. Walbert serves as Chairman of the Board of Egalet Corporation and sits on the Board of Directors of XOMA Corporation , the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), the Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT, a World Business Chicago (WBC) led council of technology leaders and the Greater Chicago Arthritis Foundation . Mr. Walbert is also a member of the Illinois Innovation Council .
Financial terms:
Latest news:
